Hormonal
Uncarboxylated osteocalcin (un-OC) acts as an endocrine hormone that regulates energy metabolism by stimulating pancreatic beta-cell proliferation, insulin secretion, and adiponectin production, thereby improving glucose tolerance and reducing fat mass.
Current research suggests that bone health and metabolic health are linked via osteocalcin. While you cannot directly supplement osteocalcin effectively based on this text, maintaining bone health through resistance training and adequate Vitamin K intake may support this hormonal pathway. However, human causal evidence is still pending, so prioritize standard metabolic interventions (diet/exercise) first.
Recently the metabolic activity of OC, restricted to the un-carboxylated form has been demonstrated in osteoblast-specific knockout mice. This effect is mediated by the regulation of pancreatic b-cell proliferation and insulin secretion and adiponectin production by adipose tissue and leads to the regulation of glucose metabolism and fat mass.
Why this rating
Strong mechanistic evidence in knockout mice; human evidence is correlational and observational, lacking causal proof.
Source
Osteocalcin: Skeletal and extra‐skeletal effects
Anna Neve et al. · Journal of Cellular Physiology · 2012
DOI 10.1002/jcp.24278
More from this paper
- Vitamin K supplementation effectively increases gamma-carboxylated osteocalcin levels but does not significantly prevent bone loss or reduce fracture risk in elderly populations.Good
- Osteocalcin regulates bone mineralization by inhibiting hydroxyapatite crystal growth and nucleation, although its absence leads to smaller, less perfect crystals rather than a total failure of mineralization.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →